REDWOOD CITY, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. , today announced that it will hold its year end financial results and accomplishments conference call and webcast on Wednesday, March 1st at 4:30 p.m. EST.
To access the live teleconference, dial 800-810-0924 (U.S.) or 913-981-4900 (international).
The company also announced that Michael Ostrach, the company’s chief operating officer and general counsel, is scheduled to present at the Citigroup Investment Research Global Healthcare Conference on Monday, February 27th at 4:50 p.m. EST. The conference will be held at the Mayflower Hotel in Washington, D.C.
Live and archived audio webcasts of both presentations will also be available online via the Investor portion of Threshold’s website at www.thresholdpharm.com.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery, development and commercialization of small molecule therapeutics in middle- and late-stage clinical trials for the potential treatment of benign prostatic hyperplasia (BPH), a disease afflicting tens of millions of men worldwide, and cancer. By selectively targeting tumor or other abnormally-proliferating cells, the Company’s drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact, the statements in this press release are forward-looking statements. Such forward-looking statements include statements regarding Threshold’s product candidates, clinical trial plans and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold’s ability to initiate, enroll and complete its anticipated clinical trials, the time and expense required to conduct such clinical trials, the results of such clinical trials (including unanticipated product safety issues), and Threshold’s ability to enter into licensing or development agreements with third parties. Further information regarding these and other risks is included under the heading “Risk Factors” in Threshold’s Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on November 10, 2005 and is available from the SEC’s website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading “Investors.” We undertake no duty to update any forward-looking statement made in this news release.
Contact: Denise T. Powell Carolyn Bumgardner Wang Sr. Director, Corporate Communications WeissComm Partners, Inc. Threshold Pharmaceuticals, Inc. 415-946-1065 650-474-8206 carolyn@weisscommpartners.comdpowell@thresholdpharm.com
Threshold Pharmaceuticals, Inc.
CONTACT: Denise T. Powell, Sr. Director, Corporate Communications ofThreshold Pharmaceuticals, Inc., +1-650-474-8206, ordpowell@thresholdpharm.com; or Carolyn Bumgardner Wang of WeissCommPartners, Inc., +1-415-946-1065, or carolyn@weisscommpartners.com, forThreshold Pharmaceuticals, Inc.
Web site: http://www.thresholdpharm.com/
